Ishares Pharmaceuticals Etf Price To Earning
| IHE Etf | USD 68.39 0.33 0.48% |
iShares Pharmaceuticals ETF fundamentals help investors to digest information that contributes to IShares Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of IShares Etf. The fundamental analysis module provides a way to measure IShares Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IShares Pharmaceuticals etf.
IShares |
iShares Pharmaceuticals ETF ETF Price To Earning Analysis
IShares Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current IShares Pharmaceuticals Price To Earning | 22.36 X |
Most of IShares Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Pharmaceuticals ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
IShares Pharmaceuticals Price To Earning Component Assessment
Based on the latest financial disclosure, iShares Pharmaceuticals ETF has a Price To Earning of 22.36 times. This is much higher than that of the iShares family and notably higher than that of the Health category. The price to earning for all United States etfs is notably lower than that of the firm.
Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Fund Asset Allocation for IShares Pharmaceuticals
The fund invests 99.89% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides IShares Pharmaceuticals' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
IShares Fundamentals
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.59 | |||
| Total Asset | 381.08 M | |||
| One Year Return | 19.10 % | |||
| Three Year Return | 3.90 % | |||
| Five Year Return | 8.40 % | |||
| Ten Year Return | 4.80 % | |||
| Net Asset | 381.08 M | |||
| Last Dividend Paid | 0.31 | |||
| Equity Positions Weight | 99.89 % |
About IShares Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Pharmaceuticals ETF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iShares Pharmaceuticals ETF based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports:Check out IShares Pharmaceuticals Piotroski F Score and IShares Pharmaceuticals Altman Z Score analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.